Drug Cost
Medicare Part D could save $4.4 billion on insulin using VA prices
In 2017, Medicare Part D could have saved $4.4 billion of the $7.3 billion in post-rebate spending on insulin that year if they had used Veterans Affairs-negotiated prices, according to research published in JAMA Internal Medicine.
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
ORLANDO — The price of generic imatinib has decreased substantially in the United States over the past 2 years, according to a speaker at ASH Annual Meeting and Exposition.
1.5 million US patients miss doses of ASCVD medication due to cost
Approximately 2.2 million, or 13%, of patients with atherosclerotic CVD experience cost-related nonadherence to prescribed medication in the U.S. and approximately 9% take lower than the prescribed dose, according to findings published in Circulation.
Appropriate use of new technologies will not jeopardize MIPS score
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
IBS Care Limited by Patient Access to Medicine
More than 30 million people in the United States have irritable bowel syndrome.
Nearly 60% of rheumatology patients struggle to afford treatment
Although 90% of patients with rheumatic diseases have health insurance, 57.13% report struggling to afford their medication, with one-quarter paying more than $1,000 out of pocket each year for treatment, according to a survey from the American College of Rheumatology.
ACR: CVS-Aetna merger threatens efforts to lower drug costs
The American College of Rheumatology issued a warning on Friday that a U.S. District Court judge’s decision to allow CVS Health Corp to merge with Aetna could threaten recent progress made in forcing pharmacy benefit managers to be more transparent, and hinder efforts to reduce drug costs.
Drug costs, prior authorizations create barriers to timely cancer care
High drug costs and regulations requiring prior authorization of treatment plans are barriers to cancer treatment that can affect clinical outcomes for patients, according to results of two studies scheduled for presentation at Quality Care Symposium.
PBMs blamed for step therapy, nonmedical switching, other restrictions on patients
ORLANDO — The current role of pharmacy benefit managers as “controllers” in the center of the prescription drug market has been detrimental to both patients and physicians, according to Robert. W. Levin, MD, of Bay Area Rheumatology, in Clearwater, Florida, who likened manufacturer rebates to “kickbacks” and “organized crime.”
VIDEO: Bringing value-based medicine pricing, access to the U.S.
LOS ANGELES — In this exclusive video from GI Outlook 2019, James C. Robinson, PhD, MPH, professor of health economics at the University of California Berkeley, discusses the steps needed to bring true, value-based medicine to the United States.